In conclusion, we developed an oHSV1-FLT3L that is capable of inhibiting the growth of melanoma, glioblastoma, and pancreatic cancer cells, simultaneously inducing FLT3L secretion. This evidence concerns the gene FLT3LG and pancreatic neoplasm.